The changes in these scores in the PKG+ arm compare favourably with clinical trials of therapy for PD: among pharmacological agents, only levodopa had a similar effect on size of UPDRS III6,7 and UPDRS total scores7,8 (see Table 5 of ref. 5) and 6 months after deep brain stimulation, the UPDRS III in the “on” state (as was done in the current study) improved by 4.0 (±10) MDS-UPDRS points9 compared to 6.4 (±1.4) in this study (Table 2). The gene discussed is PRKG1; the disease is Parkinson disease.